Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.

Conclusions: Everolimus has significant anti-tumor activity in TC. While genomic profiling does not currently guide therapeutic selection in TC patients, these data have important implications when considering the use of an mTOR inhibitor in an era of precision medicine. PMID: 29301825 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29301825?dopt=Abstract

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiukiewicz K, Thomas T, Nehs MA, Marqusee E, Lee SL, Janne PA, Lorch JH Tags: Clin Cancer Res Source Type: research